Published in Cancer Weekly, April 10th, 2006
"Recent clinical trials suggest that adjuvant chemotherapy provides a survival advantage for patients with completely resected NSCLC yet many patients receive chemotherapy without benefit. Tumor in vitro resistance to antineoplastic agents is highly predictive of clinical unresponsiveness to chemotherapy for some cancers; however, little is known of the prevalence of extreme chemotherapy drug resistance for human NSCLC tumors," scientists writing in the journal Annals of Thoracic Surgery reported.
"Chemoresistance testing may be a way to predict...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.